UCB (company)

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "UCB" company – news · newspapers · books · scholar · JSTOR (December 2010) (Learn how and when to remove this message)

UCB S.A.

Company type	Société anonyme
Traded as	Euronext Brussels: UCB BEL 20 component
Industry	Pharmaceuticals
Predecessor	Compagnie Continentale du Pégamoïd Union des Fabriques Belges de Textiles Artificiels
Founded	1928
Headquarters	Brussels, Belgium
Key people	Gerhard Mayr (Chairman), Jean Christophe Tellier (CEO)
Products	Biopharmaceuticals
Revenue	€ 5.777 billion (2021)[1]
Operating income	€ 1.109 billion (2018)[1]
Net income	€ 0.823 billion (2018)[1]
Number of employees	7,600 (2020)[1]
Website	www.ucb.com

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016^[2] which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.^[2] The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee.